Targeted delivery of a novel group of site-directed transglutaminase inhibitors to the liver using liposomes: a new approach for the potential treatment of liver fibrosis

References

• Adrian JA. (2007). Addressing liver fibrosis with liposomes targeted to hepatic stellate cells. J Liposome Res, 17, 205–218.
   PubMed Web of Science ®Google Scholar
• Allen TM, Hansen C. (1991). Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta, 1068, 133–141.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR (2004). Drug delivery systems: entering the mainstream. Science, 303, 1818–1822.
   PubMed Web of Science ®Google Scholar
• Arthur MJ. (2002). Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology, 122, 1525–1528.
   PubMed Web of Science ®Google Scholar
• Bangham AD. (1992). Liposomes: realizing their promise. Hosp Pract (Off Ed), 27, 51–56, 61.
   PubMed Web of Science ®Google Scholar
• Bataller R, Brenner DA. (2005). Liver fibrosis. J Clin Invest, 115, 209–218.
   PubMed Web of Science ®Google Scholar
• Collighan RJ, Griffin M. (2009). Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. Amino Acids, 36, 659–670.
   PubMed Web of Science ®Google Scholar
• Day CP. (2002). Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut, 50, 585–588.
   PubMed Web of Science ®Google Scholar
• Devine DV, Wong K, Serrano K, Chonn A, Cullis PR. (1994). Liposome–complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta, 1191, 43–51.
   PubMed Web of Science ®Google Scholar
• Dufour MC, Stinson FS, Caces MF. (1993). Trends in cirrhosis morbidity and mortality: United States, 1979–1988. Semin Liver Dis, 13, 109–125.
   PubMed Web of Science ®Google Scholar
• Edwards KA, Baeumner AJ. (2006). Analysis of liposomes. Talanta, 68, 1432–1441.
   PubMed Web of Science ®Google Scholar
• Fesus L, Piacentini M. (2002). Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci, 27, 534–539.
   PubMed Web of Science ®Google Scholar
• Friedman SL. (2000). Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem, 275, 2247–2250.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Papahadjopoulos D. (1988). Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA, 85, 6949–6953.
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. (1995). Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol, 13, 527–537.
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Davis C. (1979). Stability of liposomes in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells. Biochem Biophys Res Commun, 89, 1287–1293.
   PubMed Web of Science ®Google Scholar
• Grenard P, Bresson-Hadni S, El Alaoui S, Chevallier M, Vuitton DA, Ricard-Blum S. (2001). Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis. J Hepatol, 35, 367–375.
   PubMed Web of Science ®Google Scholar
• Griffin M, Coutts IG, Saint RE. (2004). Patent No. WO2004/113363. UK.
   Google Scholar
• Griffin M, Casadio R, Bergamini CM. (2002). Transglutaminases: nature’s biological glues. Biochem J, 368, 377–396.
   PubMed Web of Science ®Google Scholar
• Griffin M, Mongeot A, Collighan R, Saint RE, Jones RA, Coutts IG, Rathbone DL. (2008). Synthesis of potent water-soluble tissue transglutaminase inhibitors. Bioorg Med Chem Lett, 18, 5559–5562.
   PubMed Web of Science ®Google Scholar
• Griffin M, Smith LL, Wynne J. (1979). Changes in transglutaminase activity in an experimental model of pulmonary fibrosis induced by paraquat. Br J Exp Pathol, 60, 653–661.
   PubMed Web of Science ®Google Scholar
• Huang L, Haylor JL, Hau Z, Jones RA, Vickers ME, Wagner B, Griffin M, Saint RE, Coutts IG, El Nahas AM, Johnson TS. (2009). Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int, 76, 383–394.
   PubMed Web of Science ®Google Scholar
• Huong TM, Ishida T, Harashima H, Kiwada H. (2001). The complement system enhances the clearance of phosphatidylserine (PS)-liposomes in rat and guinea pig. Int J Pharm, 215, 197–205.
   PubMedGoogle Scholar
• Hwang KJ. (1987). Liposome pharmacokinetics. In: Ostro MJ (ed.), Liposomes: From Biophysics to Therapeutics. New York: Marcel Dekker, pp. 109–156.
   Google Scholar
• Johnson TS, Fisher M, Haylor JL, Hau Z, Skill NJ, Jones R, Saint R, Coutts I, El Nahas AM, Griffin M. (2008). Transglutaminase inhibition ameliorates tissue scarring and fibrosis: experience in a kidney model. J Am Soc, 14, 2052–2062.
   Google Scholar
• Johnson TS, Griffin M, Thomas GL, Skill J, Cox A, Yang B, Nicholas B, Birckbichler PJ, Muchaneta-Kubara C, Meguid El Nahas A. (1997). The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest, 99, 2950–2960.
   PubMed Web of Science ®Google Scholar
• Johnson TS, Skill NJ, El Nahas AM, Oldroyd SD, Thomas GL, Douthwaite  JA, Haylor JL, Griffin M. (1999). Transglutaminase transcription and antigen translocation in experimental renal scarring. J Am Soc Nephrol, 10, 2146–2157.
   PubMed Web of Science ®Google Scholar
• Li F, Wang JY. (2009). Targeted delivery of drugs for liver fibrosis. Expert Opin Drug Deliv, 6, 531–541.
   PubMed Web of Science ®Google Scholar
• Massing U, Fuxius S. (2000). Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist Updat, 3, 171–177.
   PubMed Web of Science ®Google Scholar
• Mirza A, Liu SL, Frizell E, Zhu J, Maddukuri S, Martinez J, Davies P, Schwarting R, Norton P, Zern MA. (1997). A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. Am J Physiol, 272, G281–G288.
   PubMed Web of Science ®Google Scholar
• Mohammed AR, Weston N, Coombes AG, Fitzgerald M, Perrie Y. (2004). Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability. Int J Pharm, 285, 23–34.
   PubMed Web of Science ®Google Scholar
• Patel HM. (1992). Influence of lipid composition on opsonophagocytosis of liposomes. Res Immunol, 143, 242–244.
   PubMedGoogle Scholar
• Perrie Y, Barralet JE, McNeil S, Vangala A. (2004). Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route. Int J Pharm, 284, 31–41.
   PubMed Web of Science ®Google Scholar
• Perrie Y, Rades T. (2009). FASTtrack Pharmaceutics—Drug Delivery and Targeting. London: Pharmaceutical Press.
   Google Scholar
• Qiu JF, Zhang ZQ, Chen W, Wu ZY. (2007). Cystamine ameliorates liver fibrosis induced by carbon tetrachloride via inhibition of tissue transglutaminase. World J Gastroenterol, 13, 4328–4332.
   PubMed Web of Science ®Google Scholar
• Ranade VV. (1989). Drug delivery systems. 1. Site-specific drug delivery using liposomes as carriers. J Clin Pharmacol, 29, 685–694.
   PubMed Web of Science ®Google Scholar
• Sarem M, Znaidak R, Macías M, Rey R. (2006). [Hepatic stellate cells: it’s role in normal and pathological conditions]. Gastroenterol Hepatol, 29, 93–101.
   PubMedGoogle Scholar
• Semple SC, Chonn A, Cullis PR. (1996). Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry, 35, 2521–2525.
   PubMed Web of Science ®Google Scholar
• Shweke N, Boulos N, Jouanneau C, Vandermeersch S, Melino G, Dussaule JC, Chatziantoniou C, Ronco P, Boffa JJ. (2008). Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol, 173, 631–642.
   PubMed Web of Science ®Google Scholar
• Skill NJ, Griffin M, El Nahas AM, Sanai T, Haylor JL, Fisher M, Jamie MF, Mould NN, Johnson TS. (2001). Increases in renal epsilon-(gamma-glutamyl)-lysine crosslinks result from compartment-specific changes in tissue transglutaminase in early experimental diabetic nephropathy: pathologic implications. Lab Invest, 81, 705–716.
   PubMed Web of Science ®Google Scholar
• Slaughter TF, Achyuthan KE, Lai TS, Greenberg CS. (1992). A microtiter plate transglutaminase assay utilizing 5-(biotinamido)pentylamine as substrate. Anal Biochem, 205, 166–171.
   PubMed Web of Science ®Google Scholar
• Telci D, Griffin M. (2006). Tissue transglutaminase (TG2)—a wound response enzyme. Front Biosci, 11, 867–882.
   PubMed Web of Science ®Google Scholar
• Terwogt JM, Schellens JH, Huinink WW, Beijnen JH. (1999). Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat Rev, 25, 83–101.
   PubMed Web of Science ®Google Scholar
• Vemuri S, Rhodes CT. (1995). Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv, 70, 95–111.
   PubMedGoogle Scholar
• Weiner N, Martin F, Ria M. (1989). Liposomes as a drug delivery system. Drug Dev Ind Pharm, 15, 1523–1554.
   Web of Science ®Google Scholar
• Wu J, Liu P, Zhu J, Maddukuri S, Mark A, Zern MD. (2003). Increased liver uptake of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents. Hepatology, 27, 772–778.
   Google Scholar
• Yu HY, Lin CY. (1997). Uptake of charged liposomes by the rat liver. J Formos Med Assoc, 96, 409–413.
   PubMed Web of Science ®Google Scholar